

Vigilancia de la Parálisis Flácida Aguda en las Américas

Vol. 35, No.34

Semana que termina el 22 de agosto del 2020

Tabla No.1
Casos PFA esperados y reportados, 2020

| Sub región | País | Población <15 años* | Casos PFA esperados | Casos PFA reportados 2020/34 |
|--------------|------|---------------------|---------------------|------------------------------|
| AND | BOL | 3,518,376 | 35 | 6 |
| | COL* | 11,297,750 | 113 | 0 |
| | ECU | 4,771,737 | 48 | 0 |
| | PER | 8,826,539 | 88 | 32 |
| | VEN | 8,801,443 | 88 | 31 |
| BRA | BRA | 45,418,678 | 454 | 108 |
| CAP | CRI | 1,056,871 | 11 | 11 |
| | GTM | 6,149,723 | 61 | 15 |
| | HND | 2,490,741 | 25 | 35 |
| | NIC | 1,788,084 | 18 | 9 |
| | PAN | 1,089,927 | 11 | 7 |
| SLV | SLV | 1,565,217 | 16 | 4 |
| | CAR | CAR | 1,739,441 | 17 |
| LAC | CUB | 1,742,844 | 17 | 10 |
| | DOM | 3,144,441 | 31 | 3 |
| | HTI | 3,631,337 | 36 | 3 |
| MEX | MEX | 34,611,688 | 346 | 356 |
| NOA | CAN | 6,045,577 | 60 | 7 |
| | USA | 61,851,315 | NR | NR |
| SOC | ARG | 11,041,661 | 110 | 34 |
| | CHL | 3,567,505 | 36 | 2 |
| | PRY | 2,017,183 | 20 | 8 |
| | URY | 722,459 | 7 | 0 |
| Total | | 226,890,537 | 1648 | 647 |

Tabla No.2
Casos PFA bajo investigación (Todas las edades)

| País | Total 2019 | Acum. 2020 | Semana | | | | | | | | | | | |
|--------------|------------|------------|------------|----------|----------|----------|----------|----------|----------|----------|----------|-----|-----|--|
| | | | 1-26 | 27 | 28 | 29 | 30 | 31 | 32 | 33 | 34 | | | |
| BOL | 1 | 4 | 4 | 0 | 0 | 0 | 0 | 0 | ... | ... | ... | ... | ... | |
| COL* | 0 | 0 | 0 | ... | ... | ... | ... | ... | ... | ... | ... | ... | ... | |
| ECU | 5 | ... | ... | ... | ... | ... | ... | ... | ... | ... | ... | ... | ... | |
| PER | 18 | 18 | 17 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| VEN | 9 | 26 | 23 | 2 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | ... | ... | |
| BRA | 0 | 38 | 30 | 2 | 0 | 2 | 3 | 0 | 1 | 0 | 0 | 0 | 0 | |
| CRI | 0 | 6 | 6 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| GTM | 1 | 6 | 1 | 1 | 2 | 0 | 0 | 2 | 0 | 0 | 0 | ... | ... | |
| HND | 0 | 17 | 10 | 0 | 0 | 3 | 0 | 0 | 3 | 1 | 0 | 0 | 0 | |
| NIC | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 1 | |
| PAN | 0 | 7 | 7 | ... | ... | ... | ... | ... | ... | ... | ... | ... | ... | |
| SLV | 2 | 3 | 3 | 0 | ... | ... | ... | ... | ... | ... | ... | ... | ... | |
| CAR | 0 | 3 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | |
| CUB | 3 | 3 | 2 | 1 | 0 | 0 | 0 | ... | ... | ... | ... | ... | ... | |
| DOM | 1 | 3 | 3 | ... | ... | ... | ... | ... | ... | ... | ... | ... | ... | |
| HTI | 4 | 4 | 3 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| MEX | 19 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | |
| CAN | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ... | ... | ... | ... | ... | |
| USA | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR | |
| ARG | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| CHL | 8 | 0 | 0 | ... | ... | ... | ... | ... | ... | ... | ... | ... | ... | |
| PRY | 0 | 6 | 3 | 0 | 0 | 0 | 1 | 2 | 0 | 0 | 0 | 0 | 0 | |
| URY | 4 | 0 | 0 | ... | ... | ... | ... | ... | ... | ... | ... | ... | ... | |
| Total | 75 | 147 | 114 | 7 | 3 | 6 | 4 | 4 | 6 | 2 | 1 | | | |

* Reportada por países

NR - No reporta

... - Sin datos

*COL data al 27 Junio 2020 (últimos datos aplicables recibidos)

Tabla No.3 Casos de polio confirmados y compatibles, e indicadores de vigilancia de PFA, 2020 y 2019

| Sub región | País | Polio 2020 | | Casos PFA e indicadores, últimas 52 semanas (2019/35 - 2020/34) | | | | | Polio 2019 | | Casos PFA e indicadores, 2019 (2019/1 - 2019/52) | | | | |
|----------------|------|------------|------------|---|-------------|-----------------|---------------------|--------------------|------------|------------|--|-------------|-----------------|---------------------|--------------------|
| | | Confirmado | Compatible | Casos | Tasa | % Inv. <48 hrs. | % muestra adecuada* | % unid. notifican. | Confirmado | Compatible | Casos | Tasa | % Inv. <48 hrs. | % muestra adecuada* | % unid. notifican. |
| AND | BOL | 0 | 0 | 12 | 0.34 | 100 | 83 | ... | 0 | 0 | 24 | 0.68 | 92 | 79 | ... |
| | COL* | 0 | 0 | 5 | 0.04 | 80 | 100 | 96 | 0 | 0 | 76 | 0.67 | 67 | 95 | 97 |
| | ECU | 0 | 0 | ... | ... | ... | ... | ... | 0 | 0 | 22 | 0.46 | 82 | 86 | ... |
| | PER | 0 | 0 | 62 | 0.76 | 71 | 74 | 6 | 0 | 0 | 121 | 1.47 | 74 | 68 | 6 |
| | VEN | 0 | 0 | 72 | 0.92 | 99 | 46 | ... | 0 | 0 | 101 | 1.29 | 100 | 60 | ... |
| BRA | BRA | 0 | 0 | 251 | 0.57 | 99 | 69 | 96 | 0 | 1 | 449 | 1.01 | 98 | 64 | 96 |
| CAP | CRI | 0 | 0 | 17 | 1.60 | 82 | 94 | 100 | 0 | 0 | 16 | 1.50 | 94 | 81 | 99 |
| | GTM | 0 | 0 | 44 | 0.74 | 98 | 77 | 100 | 0 | 1 | 71 | 1.19 | 85 | 77 | 100 |
| | HND | 0 | 0 | 46 | 1.51 | 85 | 93 | 90 | 0 | 0 | 46 | 1.51 | 67 | 93 | 90 |
| | NIC | 0 | 0 | 16 | 0.82 | 94 | 94 | 100 | 0 | 0 | 25 | 1.28 | 100 | 100 | 100 |
| | PAN | 0 | 0 | 12 | 1.06 | 33 | 100 | 90 | 0 | 0 | 6 | 0.53 | 67 | 100 | 88 |
| SLV | 0 | 0 | 11 | 0.63 | 64 | 82 | 9 | 0 | 0 | 34 | 1.96 | 50 | 91 | 14 | |
| CAR | CAR | 0 | 0 | 1 | 0.05 | ... | ... | 76 | 0 | 0 | 2 | 0.11 | 100 | 100 | 83 |
| LAC | CUB | 0 | 0 | 23 | 1.27 | 87 | 91 | 100 | 0 | 0 | 28 | 1.54 | 75 | 93 | 100 |
| | DOM | 0 | 0 | 16 | 0.54 | 31 | 94 | ... | 0 | 0 | 25 | 0.84 | 28 | 92 | ... |
| | HTI | 0 | 0 | 6 | 0.16 | 67 | 50 | 89 | 0 | 0 | 14 | 0.38 | 86 | 43 | 85 |
| MEX | MEX | 0 | 0 | 688 | 2.06 | 100 | 83 | 44 | 0 | 0 | 840 | 2.51 | 100 | 88 | 40 |
| NOA | CAN | 0 | 0 | 17 | 0.29 | ... | 35 | ... | 0 | 0 | 26 | 0.44 | ... | 38 | ... |
| | USA | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR |
| SOC | ARG | 0 | 0 | 93 | 0.84 | 34 | 81 | ... | 0 | 0 | 183 | 1.66 | 29 | 73 | 100 |
| | CHL | 0 | 0 | 26 | 0.70 | 85 | 65 | 81 | 0 | 0 | 61 | 1.65 | 84 | 67 | 94 |
| | PRY | 0 | 0 | 18 | 0.88 | 94 | 89 | 96 | 0 | 0 | 26 | 1.26 | 88 | 92 | 93 |
| | URY | 0 | 0 | 0 | ... | ... | ... | ... | 0 | 0 | 8 | 1.13 | 100 | ... | ... |
| Total § | | 0 | 0 | 1436 | 0.92 | 90 | 78 | - | 0 | 2 | 2204 | 1.41 | 86 | 77 | ... |

+ Tomado dentro de los primeros 14 días del inicio de parálisis

... - Sin datos

CAR incluye informes de países miembros de CARPHA

§ Excluyendo a EUA

NR - No reportando

*COL data al 27 Junio 2020 (últimos datos aplicables recibidos)

Sólo se incluyen datos de casos de PFA en menores de 15 años en tablas 1 y 2

El boletín de vigilancia de la poliomielitis se encuentra en: www.paho.org/inmunizacion/BoletinPolio



Tabla No.1
Resultados e indicadores de aislamiento viral, últimas 52 semanas
Semanas epidemiológicas 2019/35 - 2020/34

| Lab. | País | Número de muestras de casos de PFA | Prueba de aislamiento viral | | | | | | | | | | % muestras positivas de NPEV | Tiempo para el resultado de aislamiento | | |
|---------------------|------|------------------------------------|-----------------------------|-------------------|-------------------|------------------|-------------------|-----------|------------|----------|------------|----------|------------------------------|---|---|---------------------------|
| | | | Pendiente de resultados | | | Con resultados | | | | | | | | Total muestras con resultado | Total con fecha de recepción y de resultado | % con resultado ≤ 14 días |
| | | | Aún no en lab. | Recibido ≤14 días | Recibido >14 días | Sólo polio virus | Poliovirus y NPEV | Sólo NPEV | Negativo | Otros | Inadecuado | | | | | |
| CAR | DOM | 16 | 3 | 0 | 0 | 0 | 0 | 0 | 13 | 0 | 0 | 0 | 13 | 13 | 92 | |
| | HND | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 2 | 2 | 100 | |
| | HTI | 7 | 2 | 0 | 0 | 0 | 0 | 1 | 4 | 0 | 0 | 20 | 5 | 5 | 40 | |
| | NIC | 15 | 1 | 0 | 0 | 0 | 0 | 3 | 11 | 0 | 0 | 21 | 14 | 14 | 50 | |
| | PAN | 6 | 6 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| CDC | CRI | 16 | 1 | 0 | 2 | 0 | 0 | 5 | 8 | 0 | 0 | 38 | 13 | 12 | 67 | |
| | GTM | 43 | 7 | 0 | 1 | 0 | 0 | 7 | 28 | 0 | 0 | 20 | 35 | 27 | 33 | |
| | HND | 26 | 0 | 0 | 1 | 0 | 0 | 2 | 23 | 0 | 0 | 8 | 25 | 25 | 100 | |
| | PAN | 6 | 1 | 0 | 0 | 0 | 0 | 3 | 2 | 0 | 0 | 60 | 5 | 5 | 0 | |
| | PRY | 18 | 6 | 0 | 0 | 0 | 0 | 2 | 10 | 0 | 0 | 17 | 12 | 12 | 33 | |
| | SLV | 10 | 0 | 0 | 7 | 0 | 0 | 0 | 3 | 0 | 0 | 0 | 3 | 3 | 0 | |
| CENET | BOL | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| FIO | BRA | 203 | 14 | 0 | 10 | 4 | 0 | 6 | 169 | 0 | 0 | 6 | 179 | 179 | 73 | |
| | PER | 49 | 9 | 0 | 0 | 0 | 0 | 0 | 40 | 0 | 0 | 0 | 40 | 40 | 70 | |
| IEC | BRA | 3 | 2 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 1 | 0 | |
| INDRE | MEX | 582 | 0 | 14 | 37 | 3 | 0 | 49 | 482 | 0 | 0 | 10 | 534 | 533 | 99 | |
| INH | VEN | 43 | 15 | 0 | 2 | 0 | 0 | 5 | 21 | 0 | 0 | 19 | 26 | 26 | 19 | |
| INS | COL* | 5 | 0 | 0 | 0 | 0 | 0 | 0 | 5 | 0 | 0 | 0 | 5 | 5 | 60 | |
| IPK | CUB | 23 | 2 | 0 | 4 | 0 | 0 | 0 | 17 | 0 | 0 | 0 | 17 | 17 | 82 | |
| ISP | CHL | 21 | 0 | 0 | 0 | 0 | 0 | 0 | 21 | 0 | 0 | 0 | 21 | 21 | 95 | |
| MAL | ARG | 85 | 0 | 0 | 1 | 0 | 0 | 6 | 78 | 0 | 0 | 7 | 84 | 80 | 83 | |
| | BOL | 10 | 2 | 0 | 6 | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 2 | 2 | 0 | |
| (sin nombre de lab) | BOL | 2 | 0 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| | CAN | 6 | 0 | 0 | 0 | 0 | 0 | 0 | 6 | 0 | 0 | 0 | 6 | 0 | 0 | |
| | CRI | 2 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| | HND | 18 | 17 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 1 | 100 | |
| | PER | 7 | 7 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| | VEN | 7 | 6 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 100 | 1 | 1 | 0 | |
| Total | | 1232 | 102 | 14 | 75 | 7 | 0 | 90 | 947 | 0 | 0 | 9 | 1044 | 1024 | 85 | |

... Sin datos Sólo se incluyen muestras de heces de casos de PFA en menores de 15 años

*COL data al 27 Junio 2020 (últimos datos aplicables recibidos)

Tabla No.2
Estado de pruebas de diferenciación intratípica (ITD) para muestras con aislamiento de poliovirus, últimas 52 semanas
Semanas epidemiológicas 2019/35 - 2020/34

| Lab. | País | Número de poliovirus aislados | Resultado de diferenciación intratípica de poliovirus | | | | | | | | | Pendiente de resultado ITD | Número de muestras con resultado ITD | Resultado ITD con fechas de recepción o detección y resultado | % con resultado ITD ≤ 7 días de la recepción o detección | % con resultado ITD ≤ 45 días del inicio de parálisis | % con resultado ITD ≤ 60 días del inicio de parálisis |
|--------------|------|-------------------------------|---|----------|----------|----------|----------|----------|----------|----------|----------|----------------------------|--------------------------------------|---|--|---|---|
| | | | Sabin | | | VDPV | | | Salvaje | | | | | | | | |
| | | | P1 | P2 | P3 | P1 | P2 | P3 | P1 | P2 | P3 | | | | | | |
| FIO | BRA | 4 | 2 | 0 | 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 4 | 4 | 100 | 75 | 75 |
| INDRE | MEX | 3 | 2 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 3 | 100 | 100 | 100 |
| Total | | 7 | 4 | 0 | 6 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 7 | 7 | 100 | 86 | 86 |